Skip to content
Screener

Cogent Biosciences, Inc. COGT Q4 2025 Annual earnings

Reported February 17, 2026 · Before market open

EPS-$0.55Miss by $0.04
Revenue estimate$1.7M
EPS estimate-$0.51

Next report

Aug 10, 2026 (In 3 days)
Revenue estimate$1.0K
EPS estimate-$0.55

Financials

Q4 2025

Income statement

See full
Operating income-$99.5M-34.9%
Net income-$102.5M-50.9%
EPS (diluted)-$0.61-22.0%

Balance sheet

See full
Cash & equivalents$312.0M+218%
Total debt$15.9M-9.0%
Total equity$636.4M+148%
Total assets$937.6M+186%

Cash flow

See full
Operating cash flow-$79.1M-30.6%
CapEx$811.0K+981%
Free cash flow-$79.9M-31.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5.45B+533%
Enterprise value$5.16B+560%

Returns & leverage

See full
Return on equity-73.7%-15.2pp
Debt / equity0×0.0×
Current ratio14.2×+8.9×

FAQ

When did Cogent Biosciences, Inc. report Q4 2025 earnings?
Cogent Biosciences, Inc. (COGT) reported Q4 2025 earnings on February 17, 2026 before market open.
What were Cogent Biosciences, Inc.'s Q4 2025 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.55 for Q4 2025.
Did Cogent Biosciences, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.51 by $0.04.
How did Cogent Biosciences, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 511.1% from $-0.09.
Where can I find Cogent Biosciences, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-053131) and the 10-K periodic report (0001193125-26-053334) directly on SEC EDGAR. The filing index links above go to sec.gov.